XTL Biopharmaceuticals
XTLB
4 hedge funds and large institutions have $596K invested in XTL Biopharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
13% less capital invested
Capital invested by funds: $687K → $596K (-$91K)
33% less funds holding
Funds holding: 6 → 4 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$942 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$35K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$26K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.83K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NC
1
Noked Capital
Tel Aviv,
Israel
| $272K | – | – | – |
|
|
NI
2
Noked Israel
Ramat Hasharon,
Israel
| $272K | – | – | – |
|
|
3
Morgan Stanley
New York
| $50K | +$942 | +175 | +2% |
|
|
4
UBS Group
Zurich,
Switzerland
| $2K | -$2.83K | -526 | -63% |
|
|
5
Invesco
Atlanta,
Georgia
| – | -$35K | -6,490 | Closed |
|
|
6
Citadel Advisors
Miami,
Florida
| – | -$26K | -4,564 | Closed |
|
XTLB Hedge Fund Activity: Q4 2019 in Review
4 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q4 2019, worth a combined $596K — down 13% from $687K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of XTLB and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Morgan Stanley, adding an estimated $942. The largest seller was Invesco, exiting entirely with an estimated $35K sold.
- 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q4 2019, down from 6 in Q3 2019.
- Funds reported $596K of XTL Biopharmaceuticals stock for Q4 2019, down 13% quarter-over-quarter.
- 0 funds opened new XTL Biopharmaceuticals positions in Q4 2019 and 2 closed out, a net change of -2 holders.
- The largest XTL Biopharmaceuticals buyer in Q4 2019 was Morgan Stanley, an estimated $942 added.
- The largest XTL Biopharmaceuticals seller in Q4 2019 was Invesco, an estimated $35K sold.
Based on aggregated 13F filings for Q4 2019.